Displaying 481 - 500 of 1188
Download
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-100680-PIP01-22
  • Influenza recombinant H7 haemagglutinin
  • Prevention of influenza infection
  • Vaccines
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100103-PIP01-21
  • Rozanolixizumab
  • Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease
  • Not available at present
  • Neurology
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100920-PIP01-23
  • Pneumococcal Polysaccharide Serotype 3 – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 6A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 7F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 19A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 22F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 33F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 8 – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 9N – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 10A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 11A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 12F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 17F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 15A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 15C – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 16F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 23A – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 23B – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 24F – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 31 – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 35B – Diphtheria CRM197 Conjugate
  • Pneumococcal Polysaccharide Serotype 20A – Diphtheria CRM197 Conjugate
  • Prevention of disease caused by Streptococcus pneumoniae
  • Vaccines
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100594-PIP01-22
  • N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethyl-phenyl]-3,3-dimethylbutanamide
  • Treatment of focal onset seizures
  • Neurology
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101232-PIP01-23
  • palopegteriparatide
  • Treatment of hypoparathyroidism
  • Yorvipath
  • Yorvipath
  • Endocrinology-Gynaecology-Fertility-metabolism
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101230-PIP01-23
  • teprotumumab
  • Treatment of thyroid eye disease
  • Not available at present
  • TEPEZZA
  • Ophthamology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101122-PIP01-23
  • ENFORTUMAB VEDOTIN
  • Treatment of head and neck epithelial malignant neoplasms
  • Padcev
  • Padcev
  • Padcev
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101100-PIP01-23
  • Derivative of a benzoimidazole substituted pyrimidine (PF-07220060)
  • Treatment of breast malignant neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101085-PIP01-23
  • Humanised IgG1 monoclonal antibody against integrin beta-6 conjugated to monomethyl auristatin E via a valine-citrulline linker
  • Treatment of non-small cell lung cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101355-PIP01-24
  • (3S,10S,14S)-1-[4-[[(2S)-4-carboxy-2-[(2S)-4-carboxy-2-(6-[18F] fluoropyridin-3-amido)butanamido]butanamido]methyl]phenyl]-3-[(naphthalen-2-yl)methyl]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid ([18F]PSMA-1007)
  • Visualisation of prostate specific membrane antigen in prostate cancer
  • Radelumin
  • Diagnostic
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100986-PIP02-23
  • ENCORAFENIB
  • Treatment of lung cancer
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Braftovi
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100985-PIP02-23
  • BINIMETINIB
  • Treatment of lung cancer
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Mektovi
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101270-PIP01-23
  • SEMAGLUTIDE
  • Prevention of cardiovascular events in patients with atherosclerosis
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Wegovy
  • Endocrinology-Gynaecology-Fertility-metabolism
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101090-PIP01-23
  • tiragolumab
  • Treatment of hepatocellular carcinoma
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101059-PIP01-23
  • [(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl]-trimethylazanium chloride (R-DOTAP chloride)
  • Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57) / Palmitoyl-KSS-KKLLMGTLGIVCPICSQKP(HPV-16 E7 82-98) / Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90) /Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL (HPV-16 E6 25-45)
  • Treatment of human papilloma virus (HPV) type 16 positive malignancies
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100980-PIP01-23
  • 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro- 2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop- 2-en-1-one adipate
  • Treatment of non-small cell lung cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100969-PIP01-23
  • V940 (mRNA-4157), Modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens
  • Treatment of lung cancer
  • Not available at present
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101287-PIP01-23
  • SUMATRIPTAN
  • NAPROXEN SODIUM
  • Treatment of migraine headaches
  • Suvexx 85 mg/500 mg film-coated tablets
  • FI, DK, HU, NO, SE: Nomigrin EE, LT, LV: Migsun PL: Frimig Duo
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101003-PIP01-23-M01 (update)
  • garadacimab
  • Prevention of hereditary angioedema
  • Immunology -Rheumatology-Transplantation
 PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Partial Compliance Check Granted
MHRA-101034-PIP01-23
  • Belrestotug
  • GSK4428859A
  • Treatment of lung cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
Download XLSX